Corcept Therapeutics Stock News

Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09 in the year-ago quarter. At

Upgrades According to Citigroup, the prior rating for Tractor Supply Co (NASDAQ:TSCO) was changed from Neutral to Buy. For the fourth quarter, Tractor Supply had an EPS of $1.93, compared to year-ago

The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

The mean of analysts' price targets for Corcept (CORT) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts

CORT vs. ZTS: Which Stock Is the Better Value Option?

CORT vs. ZTS: Which Stock Is the Better Value Option?

These quiet biotechs are tightly focused and practically alone in their markets.

These quiet biotechs are tightly focused and practically alone in their markets.

SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Corcept Therapeutics, Inc., Match Group, Inc., Inc., loanDepot, Inc., and Odonate Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 780-3993.

MENLO PARK, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs t

During the last session, Corcept Therapeutics Incorporated (NASDAQ:CORT)s traded shares were 4.21 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stocks price was $18.86, reflecting an intraday gain of 6.55% or $1.16. The 52-week high for the CORT share is $31.18, that puts it down Given A -65.32% Drop From High, Can Corcept Therapeutics Incorporated (NASDAQ: CORT) Quickly Recover? Read More »

Addressing obviousness in the context of method of treatment claims using particular drug dosages, the US Court of Appeals for the Federal Circuit affirmed a Patent Trial & Appeal Board (Board) final written decision holding that Teva failed to prove obviousness because it failed to show a reasonable expectation of success. Teva Pharms., LLC v. Corcept Therapeutics, Inc., Case No. 21-1360 (Fed. Cir. Dec. 7, 2021) (Moore, C.J.) By: McDermott Will & Emery

MENLO PARK, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (Corcept), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share, at a price not greater than $23.75 nor less than $20.75 per share, in cash, less any applicable withholding taxes and without interest (the Tender Offer), which expired one minute after 11:59 p.m., New York City time, on December 15, 2021.

MENLO PARK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced an update to its offer to purchase up to 10,000,000 shares of its common stock at a price not greater than $23.75 nor less than $20.75 per share closing at one minute after 11:59 P.M., New York City time, on December 15, 2021 (the “Tender Offer”).